Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trialarticle Published on 2023-11-272024-09-05 Journal: Heliyon [Category] update2024, [키워드] Casirivimab COVID-19 Efficacy Imdevimab Safety [DOI] 10.1016/j.heliyon.2023.e22839 PMC 바로가기 [Article Type] article
SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimabArticle Published on 2023-01-212024-09-05 Journal: International Journal of Infectious Diseases [Category] update2024, [키워드] Antibody therapy bamlanivimab Casirivimab COVID-19 Imdevimab Viral load [DOI] 10.1016/j.ijid.2023.01.012 PMC 바로가기 [Article Type] Article
Implementation and Patient Outcomes of a Pediatric COVID-19 Monoclonal Antibody ProgramArticle Published on 2022-12-282023-07-10 Journal: Journal of the Pediatric Infectious Diseases Socie [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 pediatric SARS-CoV-2 neutralizing antibody Sotrovimab [DOI] 10.1093/jpids/piac107 PMC 바로가기
Expediting the chromatographic analysis of COVID-19 antibody therapeutics with ultra-short columns, retention modeling and automated method developmentArticle Published on 2022-11-302022-11-15 Journal: Journal of pharmaceutical and biomedical analysis [Category] SARS, 진단, [키워드] Analysis automated Automation Casirivimab collected complementary COVID-19 COVID-19 antibody COVID-19 pandemic drug candidate Effect Emergency use authorization EUA experimental work feasible help hospitalized patient Imdevimab infected with SARS-CoV-2 mAb mAbs monoclonal antibody passive immunity performed Protein required retention Retention modeling SEC submission turnaround times Ultra-short column. Vaccines [DOI] 10.1016/j.jpba.2022.115039 PMC 바로가기
Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation ElectrophoresisArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] 진단, [키워드] added antibody assay interference B-cell bamlanivimab Casirivimab Cell characterization COVID-19 diagnostic Electrophoresis etesevimab evaluate evaluated Imdevimab Immunofixation immunofixation electrophoresis in vitro infused Interference medication monoclonal monoclonal antibody monoclonal antibody therapy neoplasm Patient patients plasma platform producing recognizing serum Serum protein serum protein electrophoresis serum sample serum samples Sotrovimab sustained tested therapeutic [DOI] 10.1093/jalm/jfac064 PMC 바로가기
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants중증급성호흡기증후군 코로나바이러스 2 델타 및 오미크론 변이체에 대한 단일클론항체의 임상적 효능 및 시험관내 중화능Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Casirivimab casirivimab/imdevimab clinical Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient decrease delta variant dosage Efficacy except for exhibit Hospital stay Imdevimab in vitro in vitro data in vivo Infection mAb mAbs monoclonal monoclonal antibodies monoclonal antibody neutralization Neutralization assay neutralization capacity neutralizing capacity neutralizing effect Omicron variant Patient patients treated performed provided receiving respiratory respiratory tract respiratory viral RNA SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus sotromivab Sotrovimab the SARS-CoV-2 therapeutic therapy treated variant Viral Virus neutralization virus neutralization assay virus neutralization assays [DOI] 10.1002/jmv.27916 PMC 바로가기 [Article Type] Article
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2SARS-CoV-2 Omicron subvariants, BA.1 및 BA.2에 대한 중화 항체 및 항바이러스 약물의 다양한 효능Article Published on 2022-09-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha Analysis antibodies antibody Antiviral antiviral drug antiviral drugs Antiviral effect antiviral effects BA.1 BA.2 Casirivimab Cell culture concentrations conserved coronavirus Delta drug treatment Efficacy EIDD-1931 Evidence FIVE Gamma Imdevimab Infection intrinsic mathematical molnupiravir Neutralizing antibodies neutralizing antibody Nirmatrelvir omicron other variant other variants quantified replacing respiratory SARS-CoV-2 sensitivity severe acute respiratory syndrome Coronavirus Sotrovimab Spread Treatment variant variants Viral [DOI] 10.1016/j.antiviral.2022.105372 PMC 바로가기 [Article Type] Article
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Randomized Controlled Trial Published on 2022-09-012022-10-04 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] administration adverse event antibody Casirivimab clinically conducted COVID-19 death defined demonstrated development dose doses double-blind Efficacy end point evaluate evaluated exploratory hypersensitivity reaction Imdevimab incidence of COVID-19 laboratory-confirmed monoclonal antibody occurred Occurrence occurrence of COVID-19 Odds ratio participant Placebo placebo-controlled trial Prevent proportion Randomized reaction reduction in Repeat reported risk reduction SARS-CoV-2 Seroconversion substantial risk Tolerability treatment period treatment-emergent adverse event uninfected volunteers [DOI] 10.1016/j.ijid.2022.06.045 PMC 바로가기 [Article Type] Randomized Controlled Trial
Annular lichenoid eruption following treatment with casirivimab/imdevimab for COVID-19Case report Published on 2022-09-012022-10-05 Journal: JAAD Case Reports [Category] 치료법, 치료제, [키워드] Casirivimab COVID-19 COVID-19 antiviral drug eruption drug reaction Imdevimab lichenoid lichenoid reaction REGN-CoV2 Treatment [DOI] 10.1016/j.jdcr.2022.07.007 [Article Type] Case report
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant코로나19 델타 변이형 환자에서 카시리비맙-임데비맙 항체 병용요법의 임상적 효능Article Published on 2022-09-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 administration age antibody cocktail antibody combination antibody treatment Casirivimab Casirivimab-imdevimab treatment clinical Clinical efficacy cocktail Combination conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death Delta delta variant dose Efficacy evaluate FIVE High flow nasal cannula high-risk patient High-risk patients hospital Hospitalization Imdevimab inclusion criteria intravenously Japan mechanical ventilation monoclonal antibodies monoclonal antibody nasal nasal cannula Neutralizing antibodies outcome oxygen Oxygen therapy Patient patients with COVID-19 receive reduce reduced respiratory risk SARS-CoV-2 significantly lower therapy Treatment treatment group Viral Viral load with COVID-19 [DOI] 10.1016/j.jiac.2022.05.012 PMC 바로가기 [Article Type] Article